Cumberland Pharmaceuticals

Duncan-Williams is maintaining its Hold rating on shares of Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX). “Our valuation is now primarily based on a DCF analysis,” Duncan-Williams writes. “We use a WACC of 14% with a terminal growth rate of 0% to arrive at a hypothetical estimate of $6.00 (...

In a recent report, Jefferies will maintain a hold rating on Cumberland Pharmaceuticals (NASDAQ: CPIX) due to marginal progress from 1Q. In the report, Jefferies said, "CPIX has gained additional formulary wins but the sales story is unchanged. After 18 months on the market, Caldolor is still...

Last night, Cumberland Pharmaceuticals (NASDAQ: CPIX) announced FDA approval for its new formulation of Acetadote, Jefferies reports. “The new formulation does not contain a common chelating agent used to stabilize the solution,” Jefferies writes. “Approval of the new formulation does not afford...

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) reported 3Q EPS of 5c on revenue of $12.2M, Jefferies & Company reports. “CPIX did post a 30% increase in placements but unfortunately that doesn't correlate with sales,” Jefferies & Company writes. “We are still not convinced that Caldolor is...